Vinflunine, the latest Vinca alkaloid in clinical development: A review of its preclinical anticancer properties

Critical Reviews in Oncology/Hematology

Volumn 40, Issue 2, 2001, Pages 159-173

  Kruczynski, Anna ^a   Hill, Bridget T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Combination chemotherapy; In vivo anticancer activity; Microtubule dynamics; Tubulin binding; Vinca alkaloid

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CASPASE INHIBITOR; CATHARANTHINE; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GLYCOPROTEIN P; MITOMYCIN C; NAVELBINE; PACLITAXEL; TUBULIN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINFLUNINE;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CLINICAL TRIAL; COLON ADENOCARCINOMA; CYTOTOXICITY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LEUKEMIA; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MICROTUBULE; MITOSIS INHIBITION; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; NEUROTOXICITY; NONHUMAN; PROTEIN BINDING; REVIEW; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE; COLONIC NEOPLASMS; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FORECASTING; HUMANS; LEUKEMIA P388; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICROTUBULES; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; NERVOUS SYSTEM DISEASES; TUBULIN MODULATORS; TUMOR CELLS, CULTURED; VINBLASTINE; VINCA ALKALOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034773326     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00183-4     Document Type: Review

References (68)

1. Antimicrotubule agents
2. Mechanism of inhibition by Vinca alkaloids
3. Modulation of microtubule dynamics by drugs: A paradigm for the actions of cellular regulators
4. Further biological activities of vincaleukoblastine-an alkaloid isolated from Vinca rosea (L.)
5. Experimental basis for clinical evaluation of anti-tumour principles derived from Vinca rosea Linn
6. Alkaloids of Vinca rosea Linn. IX. Extraction and characterisation of leurosidine and leucocristine
7. Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate
8. The Vinca alkaloids: A new class of oncolytic agents
9. Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new Vinca alkaloid
10. Application of the Polonovski reaction to the synthesis of vinblastine-type alkaloids
11. 5′-nor-anhydrovinblastine, prototype of a new class of vinblastine derivatives
12. Vinorelbine: An overview
13. Vinorelbine - A clinical review
14. Modifications in the 'upper' or velbenamine part of the Vinca alkaloids have major implications for tubulin activities
15. Cancer: Superacid generation of new antitumor agents
16. Medicinal chemistry of bisindole alkaloids from Catharanthus
17. Oxyfunctionalization of hydrocarbons. 9. Superacid-catalyzed oxygenation of alkanes
18. Hydroxylation and bromination of indolines and tetrahydroquinolines in superacids
19. Vinca alkaloids in superacidic media: A method for creating a new family of antitumour derivatives
20. The effects of vincaleukoblastine on dividing cells in vivo
21. Physiochemical aspects of tubulin-interacting antimitotic drugs
22. The effects of Vinca alkaloid interactions with tubulin
23. The action of vincaleukoblastine on mitosis in vivo
24. Dynamic instability of microtubule growth
25. Microtubule treadmilling: What goes around comes around
26. Rapid treadmilling of MAP-free brain microtubules in vitro and its suppression by tau
27. Pharmacological probes of microtubule function
28. Stoichiometry of the vinblastine-induced self-association of calf brain tubulin
29. Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends
30. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid
31. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules
32. Vinflunine, a new Vinca alkaloid: Cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells
33. The mammalian interphase centrosome: Two independent units maintained together by the dynamics of the microtubule cytoskeleton
34. NMR analyses of vinorelbine and vinflunine binding to the tubulin α/β dimer
35. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity
36. Interaction of Vinca alkaloids with tubulin: A comparison of vinblastine, vincristine, and vinorelbine
37. In vitro synergistic effects of vinflunine, a novel fluorinated Vinca alkaloid, in combination with other anticancer drugs
38. Biochemistry of multidrug resistance mediated by the multidrug transporter
39. Differing patterns of cross-resistance resulting from exposure to specific antitumour drugs or to radiation in vitro
40. Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca Alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro
41. Markedly diminished drug-resistance inducing properties of vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro, with clinical implications
42. Induction of apoptosis by vinflunine, a novel fluorinated Vinca alkaloid
43. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signalling pathways in human KB-3 carcinoma cells
44. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review
45. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts
46. Preclinical in vivo antitumour activity of vinflunine, a novel fluorinated Vinca alkaloid
47. Marked antitumour activity of vinflunine, a new fluorinated Vinca alkaloid in murine and human experimental tumours
48. Definite antitumour activity of vinflunine, a novel fluorinated Vinca alkaloid, against human tumour xenografts
49. Experimental antitumor activity of navelbine
50. Human tumour xenograft models in NCI drug development
51. Response of human tumour xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere)
52. Combined in vitro/in vivo test procedure with human tumour xenografts
53. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
54. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine. Evidence for a vascular mechanism
55. Vinca alkaloids: Anti-vascular effects in murine tumour
56. Factors determining the action of colchicine on tumour growth
57. Antineoplastic agents
58. Cellular uptake and tubulin binding properties of four Vinca alkaloids
59. Phase I trial of vinflunine (10070) a novel fluorinated Vinca alkaloid in patients (pts) with advanced solid malignancies: Final results
60. Phase I study of vinflunine given as a 10 minute intravenous infusion on a weekly schedule in patients with advanced solid tumours
61. Differential in vitro association of Vinca alkaloid-induced tubulin spiral filaments into aggregated spirals
62. Kinetochores capture astral microtubules during chromosome attachment to the mitotic spindle: Direct visualization in live newt cells
63. Directional instability of kinetochore mobility during chromosome congression and segregation in mitotic newt lung cells: A push-pull mechanism
64. Mechanisms of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine
65. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity
66. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice
67. Conducting the mitotic symphony
68. Vinflunine, a second generation novel Vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers